{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sulindac+Placebo",
    "query": {
      "intervention": "Sulindac Placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sulindac+Placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T00:58:41.345Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04207944",
      "title": "The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IPMN",
        "IPMN, Pancreatic"
      ],
      "interventions": [
        {
          "name": "Sulindac 400 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "21 Years to 85 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-07-10",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04207944"
    },
    {
      "nct_id": "NCT00368927",
      "title": "Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Precancerous Condition",
        "Stage I Non-small Cell Lung Cancer",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "sulindac",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 61,
      "start_date": "2006-08",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-05-23",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Burlington, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Burlington",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368927"
    },
    {
      "nct_id": "NCT00299195",
      "title": "A Randomized Study of Sulindac in Oral Premalignant Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Leukoplakia, Oral",
        "Benign Neoplasms"
      ],
      "interventions": [
        {
          "name": "sulindac",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2006-02-23",
      "completion_date": "2020-01-06",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00299195"
    },
    {
      "nct_id": "NCT00166426",
      "title": "Exisulind Versus Placebo After Surgical Removal of the Prostate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Exisulind",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 240,
      "start_date": "2003-02",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2009-11-16",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00166426"
    },
    {
      "nct_id": "NCT04823052",
      "title": "Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "Sulindac (HLX-0201), dose strength 1",
          "type": "DRUG"
        },
        {
          "name": "Sulindac (HLX-0201), dose strength 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Gaboxadol (HLX-0206)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Healx Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "13 Years to 40 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2022-05-25",
      "completion_date": "2022-10-19",
      "has_results": false,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04823052"
    },
    {
      "nct_id": "NCT01856322",
      "title": "Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Liver Metastasis",
        "Colorectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Sulindac",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Validate assays and shipping methods",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2013-04",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2015-10-23",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01856322"
    },
    {
      "nct_id": "NCT01187901",
      "title": "A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenomatous Polyposis Coli"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Sulindac",
          "type": "DRUG"
        },
        {
          "name": "Placebo A",
          "type": "DRUG"
        },
        {
          "name": "Placebo B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 92,
      "start_date": "2010-04",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-06-17",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01187901"
    },
    {
      "nct_id": "NCT01349881",
      "title": "S0820, Adenoma and Second Primary Prevention Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Eflornithine placebo & sulindac placebo",
          "type": "DRUG"
        },
        {
          "name": "eflornithine & sulindac placebo",
          "type": "DRUG"
        },
        {
          "name": "Eflornithine placebo & sulindac",
          "type": "DRUG"
        },
        {
          "name": "Eflornithine plus sulindac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 354,
      "start_date": "2013-08-23",
      "completion_date": "2032-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 990,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 617 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349881"
    },
    {
      "nct_id": "NCT01483144",
      "title": "Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Adenomatous Polyposis"
      ],
      "interventions": [
        {
          "name": "Eflornithine",
          "type": "DRUG"
        },
        {
          "name": "Eflornithine Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sulindac 150 MG",
          "type": "DRUG"
        },
        {
          "name": "Sulindac placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cancer Prevention Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2013-10",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2021-06-08",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01483144"
    },
    {
      "nct_id": "NCT00335504",
      "title": "Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Cancer",
        "Precancerous Condition",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "oligofructose-enriched inulin",
          "type": "DRUG"
        },
        {
          "name": "sulindac",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "atorvastatin calcium",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2006-03",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-09-04T00:58:41.345Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00335504"
    }
  ]
}